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Imbalanced protease activity has long been recognized in the progression of disease states such as cancer and inflammation. Serpins, the largest
family of endogenous protease inhibitors, target a wide variety of serine and cysteine proteases and play a role in a number of physiological and
pathological states. The expression profiles of 20 serpins and 105 serine and cysteine proteases were determined across a panel of normal and
diseased human tissues. In general, expression of serpins was highly restricted in both normal and diseased tissues, suggesting defined
physiological roles for these protease inhibitors. A high correlation in expression for a particular serpin–protease pair in healthy tissues was often
predictive of a biological interaction. The most striking finding was the dramatic change observed in the regulation of expression between
proteases and their cognate inhibitors in diseased tissues. The loss of regulated serpin–protease matched expression may underlie the imbalanced
protease activity observed in pathological states.
© 2006 Elsevier Inc. All rights reserved.Keywords: Protease; Serpin; Cancer; Imbalance; Expression profiling; Gene correlation; PCRProteases play critical roles in many normal processes such
as development, coagulation, and immunity. Therefore,
regulatory mechanisms must exist to ensure that homeostasis
is maintained. In this regard, there are endogenous inhibitors
for most of the known protease families [1]. A protease and
its cognate inhibitor may normally be closely matched in site
and amount of expression. An imbalance in expression
patterns may arise as either a causative or responsive element
in disease.Abbreviations: serpin, serine protease inhibitor; RSL, reactive site loop;
UUI, uterine urinary incontinence; BM-MNC, bone marrow mononuclear cells;
IBD, inflammatory bowel disease; DRG, dorsal root ganglion; CHF, chronic
heart failure; COPD, chronic obstructive pulmonary disease; PBMC, peripheral
blood mononuclear cells; BPH, benign prostate hyperplasia; SMC, smooth
muscle cell; B2M, β2-microglobulin; siRNA, small interfering RNA.
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doi:10.1016/j.ygeno.2006.03.017We have chosen to study the largest family of endogenous
protease inhibitors, the serpins, which target a wide variety of
serine and cysteine proteases [2,3]. Over 1000 serpins have
been identified across all species, including 37 human forms
[4]. Their function is mediated by a unique suicide substrate
mechanism, in which cleavage of an exposed substrate-like
sequence (reactive site loop, RSL) causes a dramatic confor-
mational change in the serpin, thereby trapping the protease in a
covalently bound, inactive state [5]. The first known serpin, α1-
antitrypsin (SERPINA1), is a secreted glycoprotein that is found
in high levels in the serum [6]. It is produced primarily in the
liver, but also by a few inflammatory and epithelial cell types
[7]. A primary site of action is the lung, where SERPINA1
inhibits human neutrophil elastase, preventing tissue damage.
Hereditary loss of SERPINA1 has been implicated in chronic
liver disease and emphysema, as well as an increased risk of
liver and other cancers [6,8]. Conversely, elevated plasma levels
of the serpin squamous cell carcinoma antigens SCCA1 and 2
(SERPINB3 and SERPINB4) are an established marker for this
174 S. Badola et al. / Genomics 88 (2006) 173–184disease [9,10]. Although they interact in vitro with cathepsins S,
L, and K, or cathepsin G and chymase, respectively, the
biological roles of SERPINB3 and SERPINB4 remain un-
known [11,12]. Here we suggest that expression profiling
correlation may aid in the identification of novel in vivo
functions of serpins and potential target proteases.
We utilized real-time PCR (TaqMan PCR) to determine the
expression profiles of 20 serpins and 105 serine and cysteine
proteases across a panel of 58 samples from a collection of 13
cell lines and 31 normal and 14 diseased human tissues. In
general, highly restricted expression of serpins was observed
in normal and diseased tissues, suggesting defined physio-
logical roles for these protease inhibitors. Furthermore, in
specific cases, the expression correlations observed in lung,
ovarian, breast, and prostate cancer tissues were altered
compared to normal tissues.
Results
Protease and serpin selection criteria
The entire human genomic complement of proteases (greater
than 500) and serpins (37) is relatively large [1,13]. Criteria
were therefore used to select a subset for transcription profiling.
Factors included known disease link, known target or substrate,
site of expression (tissue, intracellular or secreted), protein
structure (fold, essential catalytic or inhibitory residues), and
homology to proteins of known activity or disease relevance.
Aspartyl and metalloproteases were removed from consider-
ation, as serine (trypsin, subtilase) and cysteine proteases
account for the majority of proteases known to interact with
serpins. In this way, a total of 81 trypsin, 10 subtilase, and 14
cysteine proteases were selected for profiling (Supplemental
Table 1).Table 1
Serpin sequences
Nomenclature GenBank Common name
SERPINA1 X01683 α1-Antitrypsin
SERPINA3 X68733 α1-Antichymotrypsin
SERPINA4 L19684 Kallistatin
SERPINA5 M68516 Protein C inhibitor
SERPINA9 AX392967 Sequence 9 from Patent WO0214358
SERPINA11 BD130048 Human serine protease and serpin polypeptide
SERPINA12 AX192197 Sequence 13 from Patent WO0149729
SERPINA13 AX163789 Sequence 1 from Patent WO0138534
SERPINB1 M93056 Leukocyte elastase inhibitor
SERPINB2 J03603 Plasminogen activator inhibitor-2
SERPINB4 U19557 Squamous cell carcinoma antigen 2
SERPINB7 AF027866 Megsin
SERPINB8 L40377 Cytoplasmic antiproteinase 2
SERPINB10 U35459 Bomapin
SERPINB11 AF419954 Epipin
SERPINB12 AF411191 Yukopin
SERPINB13 AF169949 Hurpin, headpin
SERPINE3 AX407123 Sequence 5 from Patent WO0226981
SERPINI1 Z81326 Neuroserpin
SERPINI2 BC027859 Pancpin
Serpins are listed by standard nomenclature [2], GenBank nucleic acid accession
SERPINA1. RSL cleavage sites between P1/P1′ in bold are known or proposed basParticular attention was paid to disease relevance and site
of expression in the selection of serpins. This resulted in the
selection of most of the intracellular ov-serpins (clade B) [2].
Although an effort was made to avoid secreted serpins, as site
of action may not correlate well with site of expression, we
did select a small number of secreted serpins (clades A, E,
and I), based primarily on biochemical characterization and
disease biology. Several novel, previously uncharacterized
serpins were also selected. In total, 20 serpins (Table 1) were
chosen such that the method could be validated with known
interactions and that new serpin–protease pairs might be
identified de novo.
Serpin expression profile
The expression profile of 20 serpins across 58 samples from a
collection of 13 cells and 31 normal and 14 diseased human tissues
is depicted in Fig. 1A. The normalized relative expression is
represented by a light to dark color grid, which shows low to high
levels of mRNA transcripts. For example, SERPINB1 and
SERPINB8 are ubiquitously expressed, whereas SERPINI2 is
expressed only in pancreas. In general, good agreement was found
between the serpin mRNA expression patterns in this work and
previously reported results (mRNA and/or protein). This would
include serpins A1, A3, and A4 (liver, pancreas, and kidney)
[7,14,15]; A5 (pancreas, kidney, liver, and ovary) [16]; B8
(digestive tract, lung, liver, pituitary, skin, and tonsil) [17]; I1
(brain cortex, hypothalamus, pituitary, and spinal cord) [18]; and I2
(pancreas) [19]. The most striking and unexpected finding is the
restricted expression ofmost serpins. Themajority of the serpins are
expressed at “high” levels in four or fewer, often related, tissues in
our panel (Fig. 1A). This supports the hypothesis that serpin
expression is highly regulated and that imbalanced expression may
lead to pathological states.RSL (P1/P1′) Putative targets
GTEAAGAMFLEAIPM/SIPPE Trypsin, neutrophil elastase
GTEASAATAVKITLL/SALVE Cathepsin G, chymase, chymotrypsin
GTEAAAATSFAIKFF/SAQTN Kallikrein
GTRAAAATGTIFTFR/SARLN Thrombin, acrosin
GTEATAATTTKFIVR/SKDGP Unknown
GTEAGAASGLL/SQPPSLNTM Unknown
GTEGAAGTGAQTLPM/ETPLV Unknown
GSEAAAATSIQL/TPGPRPDL Unknown
GTEAAAATAGIATFC/MLMPE Neutrophil elastase, cathepsin G
GTEAAAGTGGVMTGR/TGHGG uPA
GVEAAAATAVVVVEL/SSPST Cathepsin G, chymase
GTEATAATGSNIVEK/QLPQS Plasmin
GTEAAAATAVVRNSR/CSRME Trypsin, furin
GTEAAAGSGSEIDIR/IRVPS Trypsin, thrombin
GTEAAAATGDSIAVK/SLPMR Unknown
GTQAAAATGAVVSER/SLRSW Trypsin
GTEAAAATGIGFTVT/SAPGH Cathepsins L, K
GTKASGATALLLLKRSR/IPI Unknown
GSEAAAVSGMIAISR/MAVLY Trypsin, tPA
GSEAATSTGIHIPVIM/SLAQ Unknown
number, and common name. RSL sequences were derived by alignment with
ed on serpin structure. Putative protease targets were taken from [2,3].
175S. Badola et al. / Genomics 88 (2006) 173–184The tight regulation of serpin expression is represented in
Figs. 1B and 1C. SERPINA11 (Fig. 1B), a previously unknown
patent sequence, exhibits a restricted expression pattern typical
of many serpins: very high expression in normal liver, with >30-
fold less expression in normal breast, prostate BPH (benign
prostate hyperplasia), and breast tumor. SERPINB4 (SCCA2)
(Fig. 1C) shows dramatically elevated levels of expression in
lung and prostate tumor tissues versus the corresponding normal
tissues. This finding is confirmatory of many studies in which
SERPINB4 has been identified as a marker for lung and other
types of cancer [20,21]. Low levels of expression were also seen
in normal tonsil, normal pituitary, hemangioma tumor, colon
IBD (inflammatory bowel disease), and breast tumor.
Expression correlation in normal tissues
One of the major challenges is to elucidate the functions of
serpins and proteases whose functions are unknown. Mining
expression profiles is one method to uncover gene function. It
is well reported in the literature that genes that encode proteins
that participate in the same pathway or are part of the same
protein complex are often coregulated [22]. Clusters of genes
with related functions often exhibit similar expression patterns
across a diverse collection of samples. Tissue-specific gene
expression can be used to predict tissue-specific function.
Therefore, we explored the relationship between serpins and
proteases based on the coregulation of expression in normal
human tissues.
We analyzed the expression correlation of 20 serpins (Table
1) and 105 proteases (Supplemental Table 1) across a panel of
25 normal human tissues (Supplemental Table 2). A heat map
displaying the results of this analysis is shown in Fig. 2A and
the correlation values are listed in Supplemental Table 1. Only
serpin–protease pairs with a correlation value >0.7 were
investigated further (see below). This cutoff value eliminated
most, if not all, spurious/weak correlations. We also observed
that several serpins shared distinct banding patterns of high
correlation (Fig. 2A). This primarily reflects predominant
expression in liver of serpins A1, A3, A4, and A11 with pro-
teases trypsin, KAL, IF, HTRA4, FA10, FA12, FA7, and Eos, or
in tonsil of serpins B7, B10, B11, and B13 with proteases
KLK10, KLK12, and KLK13.
We used this information to match gene expression patterns
of proteases with their putative inhibitors as a starting point to
understand functional relationships and roles played by serpin–
protease pairs under physiological conditions. To exemplify our
findings, the data obtained from two serpin–protease pairs are
depicted here. SERPINB8 is coexpressed with the subtilase-
type protease furin (Fig. 2B) and SERPINE3 with the subtilase
proprotein convertase, type 4 (PCSK4) (Fig. 2C).
SERPINB8 is broadly expressed across the panel, most
notably in liver, skeletal muscle, artery, heart, and smooth
muscle cell (SMC) coronary tissues. Furin expression matches
that of SERPINB8 in most cases, with a correlation of 0.8.
SERPINB8 inhibits furin in vitro with an overall Ki of 54 pM
[23]. Although SERPINB8 is known to inhibit several other
trypsin- and subtilase-type proteases in vitro, it is notable that theRSL contains two putative cleavage sites, RNSR↓ and RCSR↓,
which conform to the minimal furin consensus sequence
RXXR↓ [24–26]. Collectively, these data suggest that SER-
PINB8 may play a role in the regulation of furin activity in vivo.
The expression profile of SERPINE3 (Fig. 2C) is more
restricted than that of SERPINB8, with highest levels found in
neural tissues, such as brain, pituitary, and spinal cord (Fig. 1A).
PCSK4, a member of the proprotein convertase family,
correlates in expression with SERPINE3, with an acceptable
range of correlation among most of the normal tissues. The
correlation is >0.70 in neural tissues such as brain, spinal cord,
and pituitary gland (Fig. 2C and data not shown). Although the
primary site of PCSK4 expression has been reported to be in the
testes (not included in this study), our results show significant
expression in many other tissues such as neural, erythroid,
kidney, and pancreas [27]. While the target of SERPINE3 is
unknown, PCSK4 is a highly specific enzyme, preferring a
consensus sequence of KPXR↓XP [28]. A similar sequence is
found in the RSL of SERPINE3, KRSR↓IP. These data suggest
SERPINE3 as the cognate inhibitor of PCSK4 in vivo.
Expression correlation in oncology samples
Increased protease activity has been implicated in the genesis
of many tumors and metastases [29,30]. We postulate that
increased protease activity may be due to the loss of matched
expression between a protease and its paired serpin. To test this
hypothesis we analyzed the expression correlation of serpin–
protease pairs across a panel of five different normal and tumor
tissues (breast, lung, colon, ovary, and prostate) (Fig. 3). We
assumed that at least four scenarios are likely to occur during
tumorigenesis and they are described below:
(1) Expression of serpin is elevated to compensate increased
protease expression in the diseased tissue.
(2) Protease expression increases, while that of the serpin
remains unchanged, leading to imbalanced protease
activity.
(3) Serpin expression drops, while that of the protease
remains the same or increases, leading to imbalanced
protease activity.
(4) Serpin expression increases, while that of the protease
remains the same or decreases.
We present examples of the different scenarios as illustrated
by serpin–protease pairs of high expression correlation in
normal tissues. Expression of SERPINB8 and furin (Fig. 3A)
remains balanced in normal and tumor tissues from breast,
colon, lung, and ovary. Although two- to threefold increases in
furin levels are observed in colon, lung, and prostate tumors, the
level of expression of SERPINB8 increases proportionally. In
this example, serpin expression accompanies the increased
levels of protease in tumor samples. The elevated expression of
furin in lung, head and neck, and prostate cancer has been
previously reported [29,31,32]. This may allow for the
increased secretion of growth factors and matrix metallopro-
teases, which in turn leads to increased tumorigenesis and
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observed here, to compensate for elevated furin expression
levels, this effect would be ameliorated.
Expression of SERPINA5 and the trypsin-type protease
transmembrane protease, serine 3 (TMPRSS3) (Fig. 3B), is
matched in normal breast, colon, ovary, and prostate with low
levels of unmatched TMPRSS3 expression in the normal lung.
TMPRSS3 is elevated significantly, as much as 10- to 20-fold,
in breast and ovary tumors, while SERPINA5 expressionremains unchanged. Slight increases in TMPRSS3 expression
were also seen in colon and prostate. TMPRSS3 has been
previously identified as a marker in pancreatic and ovarian
cancer [33,34]. It is expressed on the surface of cells and
appears to possess cleavage specificity after basic amino acids,
such as Arg and Lys [34]. SERPINA5 (protein C inhibitor) is a
known inhibitor of thrombin and several other coagulation
proteases, all of which possess a preference for basic amino
acids [35,36].
Fig. 1. Serpin expression profile across 58 normal and diseased tissues. (A) Serpin expression profile/heat map. Gene expression profile of 20 serpins across 13 cell
types and 31 normal and 14 diseased human tissues. Real-time PCR reagents were designed to interrogate each serpin and experiments were performed on cDNA
generated from the cells and different clinical human tissues. Each clinical tissue sample is a pool of three different individuals to account for biological variability.
Boxes highlighted in red represent samples expressing serpin gene at high levels, green represents moderate levels, and yellow represents no/low expression. Gray
boxes indicate no data available for the serpin in that specific sample. (B) SERPINA11 gene expression profile across 58 human tissues and cells. SERPINA11 shows
restricted expression in breast normal, breast tumor, liver normal, prostate BPH, and tonsil normal. Liver normal exhibits the highest level of expression compared to
the rest of the tissues. (C) SERPINB4 gene expression profile across 58 human tissues and cells. SERPINB4 shows restricted expression in colon IBD, hemangioma
tumor, lung normal, pituitary gland, and prostate tumor. Lung tumor and prostate tumor show a high level of expression compared to the rest of the tissues.
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to the subtilase-type protease tripeptidyl peptidase 2 (TPP2)
is seen in normal tissues (Fig. 3C). The elevated expression
of TPP2 in colon tumor (∼10-fold) is met by increased
expression of SERPINB1. The normal role of TTP2 is the
processing of peptides for eventual display in the MHC class
I pathway. TPP2 is found as a multimer of 135-kDa subunits
and primarily functions as a relatively nonspecific tripeptidyl
aminopeptidase, though endoproteolytic cleavage can occur
[37–39]. SERPINB1 is among the most broadly expressed
serpins, suggesting a general role. It inhibits a wide variety
of elastase- and chymotrypsin-like serine proteases by
utilizing two separate sites on its RSL [40–42]. One
function of SERPINB1 may be to protect neutrophils from
elastase and other serine proteases that are highly expressed
in these cells. Both SERPINB1 and TPP2 are cytosolic
proteins and may interact. As the activity and specificity of
TPP2 are not currently well understood, the potential
interaction of SERPINB1 and TPP2 merits further
investigation.
Low, but matched, expression of SERPINA1 and the trypsin-
type protease hyaluronan binding protein 2 (HABP2) isobserved in normal tissues (Fig. 3D). Expression of HABP2
in colon tumor is elevated 18-fold versus colon normal, whereas
the levels of SERPINA1 remain unchanged. (Small changes in
lung tumor expression versus lung normal are not significant for
either HABP2 or SERPINA1.) HABP2 is a multidomain serine
protease found primarily in plasma [43–45]. It has been
identified in other studies as a significant marker for lung
adenocarcinoma [46]. SERPINA1 is associated with lung
disease, and the coexpression with HABP2 suggests these two
proteins interact in vivo. However, the fact that both the serpin
and the protease are also found in plasma may complicate the
analysis.
Discussion
Serpin expression is highly tissue specific in both normal and
diseased tissues
Strikingly, the majority of the serpins examined in this study
exhibited tightly regulated expression across a wide variety of
tissues, suggesting physiological roles that may be much more
precise than simply the general regulation of proteolysis. This is
Fig. 2. Correlation of serpin and protease expression in normal tissues. (A) Correlation plot of serpins versus proteases in normal tissues. Heat map displaying
expression correlation >0.7 between serpins and proteases in normal human tissues. Correlation values were calculated as described under Materials and methods from
serpin and protease expression values in 25 normal human tissues (Supplemental Table 2). Each serpin was matched against 105 proteases and correlation values >0.7
were further investigated (Supplemental Table 1). Several distinct banding patterns of high correlation reflect similar tissue-specific serpin expression in liver,
pancreas, and kidney (SERPINA1, A3, and A4) or tonsil (SERPINB7, 10, 11, and 13). (B) SERPINB8 with subtilase/furin. Expression profile of SERPINB8 with
furin (GenBank X17094) shows correlation value of 0.70 compared across 25 normal tissues (Supplemental Table 2). SERPINB8 is broadly expressed across the tissue
panel, most notably in liver, skeletal muscle, artery, heart, and SMC, coronary. Furin expression matches that of SERPINB8 in most cases, with a correlation of 0.8. (C)
SERPINE3 with subtilase/PCSK4 (proprotein convertase subtilisin/kexin type 4). Expression profile of SERPINE3 with PCSK4 (GenBank BC036354) shows
correlation value of >0.7 compared across neural tissues only (exception for this pair) and has acceptable correlation compared with the rest of the 25 different normal
tissues (Supplemental Table 2). The expression profile of SERPINE3 is more restricted than that of SERPINB8, with highest levels found in neural tissues, such as
brain, pituitary, and spinal cord. PCSK4, a member of the proprotein convertase family, correlates in expression with SERPINE3, with an overall value of 0.9.
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Fig. 2 (continued ).
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(pancreas), or B4 (lung cancer). This is consistent with the
numerous tissue-specific functions involving serpins, including
blood coagulation and fibrinolysis, spermatogenesis, neural
function, and prohormone conversion [2,3]. Also of interest is
that the expression patterns observed in this study often appear
clade-specific. Most clade A serpins are expressed in the major
secretory organs such as liver, pancreas, and kidney. Other
clades, such as clade B, appear more broadly expressed, but
definitive analysis must await further profiling of the remaining
human serpins. That serpin function might follow phylogenetic
classification would greatly aid in the study of previously
uncharacterized serpins and the identification of cognate
proteases.
Correlation analysis of normal tissue expression identified both
existing and plausible serpin–protease pairs
Our correlation method clearly identified an existing
interaction in one example (SERPINB8–furin) [23] and
suggested a novel interaction (SERPINE3–PCSK4) in
another. Given the small subset of proteases and inhibitors
that was examined in this study, this would indicate that
expression correlation is a useful tool in addition to standard
biochemical and cell biological methods. The technique does
appear to be more robust with subtilase- versus trypsin-type
serine proteases and cysteine proteases. This may reflect
differing biological roles and general location of each
protease class or the particular mechanism of interaction of
each serpin with its protease target. As a general rule,subtilase-type proteases are intracellular, while trypsin types
are secreted. This makes precise localization more difficult for
the trypsin-type proteases and may complicate expression
correlation efforts in some cases.
Of note is the fact that multiple serpins and proteases can
be expressed in the same tissue, such as liver, or that one
serpin may associate with multiple proteases [2,3], making it
difficult to assign partners on the basis of correlation alone.
Therefore, we promote the use of correlation data as a first
step to understanding expression patterns and to narrow down
possible serpin–protease pairings. However, we recognize
that correlation data alone are insufficient for thorough
evaluation of serpin–protease pairs and need to be combined
with other biological and biochemical information to
understand the full impact of serpin–protease pairings on
tissue homeostasis. In addition, as discussed above, when
serpin and/or protease is secreted, this approach may not be
ideal, as site of expression may not correlate with site of
action in these cases.
Serpin and protease expression varies dramatically in cancer,
resulting in an imbalance that may play a role in disease
progression or response
As the proteases examined in this studywere often chosen on the
basis of disease relevance, expression correlation may identify a
serpin as an important regulator of potentially pathogenic activity in
normal tissues. Such knowledge may be critical in understanding
the role of relatively obscure proteases such as TMPRSS3 and
HABP2 in cancer.
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that were observed. Ten-fold or greater increase was not
uncommon. That the serpin expression sometimes compensatedFig. 3. Normalized expression profile of serpin and protease pairs across five differen
protease pairs were selected based on >0.7 correlation values across 25 normal hum
Expression of SERPINB8 and furin exhibited a correlation value of 0.70 in normal tis
and tumor tissues from breast, colon, lung, and ovary, despite two- to threefold incr
TMPRSS3 (transmembrane protease, serine 3). Expression of SERPINA5 and TMPR
comparison. Expression of TMPRSS3 was upregulated in breast, colon, and ovary tu
and TPP2 (GenBank D49742) expression exhibited a correlation value of 0.78 in nor
lung tumors, and SERPINB1 levels matched the elevated expression of TPP2 in co
SERPINA1 and HABP2 (GenBank M73047) expression exhibited a correlation value
colon and lung tumor tissue samples. Elevated expression of HABP2 in colon and lwas remarkable. These serpins may represent a legitimate attempt
by the body to counterbalance overproduction of proteases. Thus
recognized, they may provide new insight into the mechanism andt normal and tumor tissues (breast, lung, colon, ovary, and prostate). The serpin–
an tissues (Supplemental Tables 1 and 2). (A) SERPINB8 and subtilase/furin.
sue comparison. Expression of SERPINB8 and furin remains balanced in normal
eases in furin levels in the colon and lung tumors. (B) SERPINA5 and trypsin/
SS3 (GenBank AF201380) exhibited a correlation value of 0.73 in normal tissue
mors. (C) SERPINB1 and subtilase/TPP2 (tripeptidyl peptidase II). SERPINB1
mal tissue comparison. Expression of SERPINB1 was upregulated in colon and
lon tumor. (D) SERPINA1 and trypsin/HABP2 (hyaluronan binding protein 2).
of 0.99 in normal tissue comparison. Expression of HABP2 was upregulated in
ung tumor is unmatched by SERPINA1.
Fig. 3 (continued ).
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can provide useful information in this regard.
For example, our data show that TMPRSS3 expression
increases 10- to 20-fold in breast and ovary tumors compared to
normal breast and ovary tissues. The expression level of its
potential inhibitor, SERPINB5, identified in this study (Fig. 3B)
remains unchanged, leading to the hypothesis that dysregulation
of TMPRSS3 activity may trigger certain events that are
necessary for either the initiation or the maintenance of
oncogenesis in these tumor types. This hypothesis can beaddressed by the use of siRNA to knockdown expression of
TMPRSS3 and/or SERPINB5 in these tumors to establish
relevance to disease initiation and/or progression.
Relationship between gene function and transcriptional
coexpression
Correlations among the transcript levels in normal tissues
were examined to illuminate the relationship between proteases
and serpins. The assumption is that alterations in gene
182 S. Badola et al. / Genomics 88 (2006) 173–184expression will manifest themselves at the level of biological
pathways or coregulated gene sets, rather than at the level of
individual genes [47]. In this approach, genes that have similar
expression patterns across a set of normal tissue samples are
hypothesized to have a functional relationship, such as physical
interaction between the encoded proteins, though coexpression
of transcripts does not necessarily imply a causal relationship
among proteins [48]. Gene-to-gene relationships based on
transcript levels are purely subjective and need further validation
by functional relationship, e.g., biological and biochemical
assays. In this paper we have made an attempt to bring certain
serpins and proteases together based on transcript-level
correlation in various normal tissues. Several pairings have
been identified, laying the foundation for future experiments.Materials and methods
Protease and serpin selection
Avariety of bioinformatic methods were used over the course of this project,
due to the evolving nature of human sequence databases during the execution of
this project. Expressed sequence tag (EST) databases were either searched
directly or clustered with d2 [49]. Genomic sequences were scanned with
FGENESH [50] or GenScan [51] to generate potential transcripts. These datasets
were then searched using TBLASTN with a defined set of protein probes or
translated HMMER searches using a Paracel GeneMatcher and appropriate
models from PFAM [52]. Protein probes for BLAST [53] were first examined for
repetitive regions or domains not of interest to the searches and these regions
masked out prior to conducting the search. Phrap [54] and BLASTNwere used to
identify overlapping ESTs or genomic predictions that overlapped each other or
EST hits. Using the clustered sequence results, GenBank accession numbers,
gene symbols, and annotations were assigned and catalogued.
Tissue and cell samples
Human biological materials were collected from two major sources: fee-for-
service tissue providers and academic collaborators. The tissue samples were
collected and frozen by liquid nitrogen within 3 h or less of surgery. In all cases,
informed consent granting use of the tissue for research purposes was obtained
from the patients prior to sample collection. Personal identifiers were stripped
from the samples and the samples were made anonymous prior to shipment to
Millennium's central biorepository, theMolecular and Biologic Resource Center.
All tissue samples were evaluated by a pathologist by hematoxylin and eosin
stain and stored at −80°C before being processed into cDNA. We generated a
panel of 58 different samples that were collected from 31 normal tissues, 14
diseased tissues, and 13 cell types. To account for biological variability, the
clinical tissue samples consist of pooled cDNA samples containing representa-
tive specimens from three different human donors, with both genders
represented, whenever possible. Oncology pools often contain representative
types of different common tumors of that organ, so as to conduct as wide a survey
as possible. Tumor sample pools are identified only by the organ of origin.
Tissue selection criteria for correlation analysis
Tissues were chosen for transcript analysis to evaluate oncology and
inflammation paradigms. Normal tissues represent all critical organs in the
human body except some of the neural tissues such as brain due to generally high
levels of transcriptional activity. Diseased tissues are more relevant to represent
oncology and inflammation-related diseases, e.g., tumors, IBD, and COPD.
RNA extraction
Total RNA extraction was carried out using RNA-STAT (Tel-Test, Inc., TX,
USA) according to themanufacturer's protocol (RNAStat 60 User Bulletin). Thepurity and integrity of the RNAwere assessed on the Agilent 2100 bioanalyzer
with the RNA 6000Nano Labchip reagent set (Agilent Technologies, CA, USA).
The RNA was quantified spectrophotometrically and treated with DNase
(Ambion, TX, USA) for 30 min at 37°C. DNase-treated RNAwas extracted from
the samples and stored at −80°C.
cDNA generation
First-strand cDNA synthesis was performed with the ABI reverse transcription
system (Applied Biosystems, CA, USA) according to the manufacturer's protocol.
The cDNA quality was assessed by generating expression profiles of 18S ribosomal
and β2-microglobulin (B2M) genes with real-time PCR (ABI 7700; Applied
Biosystems). cDNA samples were stored at −20°C.
Primers and TaqMan probe design
mRNA sequences for all proteases and serpins were derived from GenBank
(for accession numbers, see Table 1 and Supplemental Table 1) and primers and
TaqMan probes were designed with Primer Express software, version 2.0
(Applied Biosystems). We targeted the design at the 3′end of the open reading
frame of the gene. All primers were obtained from MWG Biotech (NC, USA)
and 6-carboxyfluorescein-labeled probes were obtained from Applied Biosys-
tems. For the normalization of our results, we used VIC-labeled B2M reagents
from Applied Biosystems. Each of the probes was quenched by 6-
carboxytetramethylrhodamine.
Primer and probe quality control
Each primer and probe pair was tested for PCR efficiency in a synthetic
template system. Primer and probe pairs were thoroughly tested by 7 logs of
dilution with synthetic template and also on human control cDNA. Reagents that
passed the criteria were validated for use in expression profiling experiments.
All of the protease and protease inhibitor assays provided the best result with the
highest primer and probe concentration (900 nM primers and 250 nM probe),
multiplexed with a housekeeping gene at primer limited concentration (200 nM
primers and 200 nM probe).
TaqMan real-time PCR
TaqMan PCR assays were performed on an ABI Prism 7700 sequence
detection system (Applied Biosystems). Multiplexed assay was performed with
protease or serpin reagent sets with the human B2M gene as an endogenous
control. All quantitative assays designed using ABI guidelines were run using
the same universal thermal cycling parameters. Cycling parameters were run at
50°C for 2 min, 95°C for 10 min to activate the DNA polymerase and then 40
cycles of 95°C for 15 s, 60°C for 1 min.
Data analysis
Data were analyzed using SDS 1.7 (Applied Biosystems) software. The
first step was to generate an amplification plot for every sample, which
showed ΔRn on the y axis (where Rn is the fluorescence emission intensity
of the reporter dye normalized to a passive reference) against the cycle
number on the x axis. From each amplification plot, a threshold cycle (Ct)
value was calculated, which was defined as the cycle at which a statistically
significant increase in ΔRn was first detected, and was displayed in the
graph as the intercept point of the amplification plot and threshold. The
obtained Ct values were exported to an Excel spreadsheet for further
analysis.
Relative expression calculation
Relative quantitation is used to compare the changes in steady-state mRNA
levels of two or more genes to each other, with one of them acting as an
endogenous control [55]. Normalization of target gene expression levels was
performed to compensate intra- and interkinetic RT-PCR variations. Data
normalization was carried out against an endogenous unregulated gene
183S. Badola et al. / Genomics 88 (2006) 173–184transcript. Based on the exponential amplification of the target gene, as well as
the normalizer, the amount of amplified molecules at the threshold cycle was
given by
Relative Expression ¼ 2−∂∂CT
AACT ¼ ACT;q  ACT;cb
This equation is based on the precondition that the efficiencies of target and
reference amplification are approximately equal and ∂CT,q is the difference
between target and endogenous reference control and ∂CT,cb is the calibrator
sample (no template control).
Calculation of correlation values
The Spotfire functional genomics version 7.3 software (Spotfire, Inc.,
MA, USA) tool was used to analyze the data generated from proteases and
serpins on the same subset of 25 normal tissue samples: adipose, adrenal
gland, artery, bladder, breast, colon, dorsal root ganglion, heart, kidney,
liver, lung, lymph node, ovary, nerve, pancreas, pituitary gland, prostate,
spinal cord, skeletal muscle, small intestine, spleen, stomach, thymus, tonsil,
and vein (Supplemental Table 2). The Spotfire Profile search tool was
utilized to search for similar expression profiles between two genes, serpin
and protease, based on the Pearson momentum correlation algorithm. Values
of the correlation coefficient r range from +1 to −1, where +1 indicates
highest similarity, while a completely opposite profile would give a −1 r
value. Expression profiles with identical shape had higher correlation.
The gene expression profiles of the 25 normal tissues listed above were used to
search for similarity between serpins and proteases. If the correlation value of two
genes was greater than 0.7, we arbitrarily defined the expression of those two genes
as closely correlated. For each serpin, a set of proteases was selected according to
their correlation values and the best matched proteases were investigated further by
evaluating the expression profile in normal and diseased tissues.
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